Suppliers and packagers for generic pharmaceutical drug: CARBAMAZEPINE

CARBAMAZEPINE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Ani Pharms	CARBAMAZEPINE	carbamazepine	CAPSULE, EXTENDED RELEASE;ORAL	076697	ANDA	Coupler LLC	67046-1455-3	30 CAPSULE, EXTENDED RELEASE in 1 BLISTER PACK (67046-1455-3)	2025-02-07
Ani Pharms	CARBAMAZEPINE	carbamazepine	CAPSULE, EXTENDED RELEASE;ORAL	076697	ANDA	Coupler LLC	67046-1558-3	30 CAPSULE, EXTENDED RELEASE in 1 BLISTER PACK (67046-1558-3)	2025-04-29
Ani Pharms	CARBAMAZEPINE	carbamazepine	CAPSULE, EXTENDED RELEASE;ORAL	076697	ANDA	Coupler LLC	67046-1559-3	30 CAPSULE, EXTENDED RELEASE in 1 BLISTER PACK (67046-1559-3)	2025-04-29

Carbamazepine Drug Supply Chain Analysis

Last updated: February 19, 2026

This report details key suppliers and manufacturing capabilities for carbamazepine, a critical anticonvulsant and mood-stabilizing medication. The analysis focuses on active pharmaceutical ingredient (API) manufacturers and contract development and manufacturing organizations (CDMOs) supporting carbamazepine production. Market dynamics, regulatory considerations, and potential supply chain risks are assessed.

What is Carbamazepine?

Carbamazepine is an anticonvulsant and mood-stabilizing drug used to treat epilepsy, trigeminal neuralgia, and bipolar disorder. Its primary mechanism of action involves blocking voltage-gated sodium channels, which inhibits repetitive neuronal firing. Carbamazepine is classified as a World Health Organization Essential Medicine, highlighting its importance in global healthcare systems [1]. The drug is available in various dosage forms, including immediate-release and extended-release tablets, oral suspensions, and capsules.

Who Manufactures Carbamazepine API?

Several companies globally produce carbamazepine active pharmaceutical ingredient (API). These manufacturers are critical to the downstream formulation of the final drug product. Key API suppliers include:

• Loba Chemie Pvt. Ltd. Based in India, Loba Chemie is a manufacturer and supplier of laboratory chemicals, including carbamazepine API. The company operates under Good Manufacturing Practice (GMP) standards.
• Merck KGaA While primarily known for a broad range of pharmaceutical products, Merck KGaA (operating as EMD Serono in the U.S. and Canada) has historically been involved in the production of key APIs, including carbamazepine. Their focus is often on high-purity, pharmaceutical-grade materials.
• Abbott Laboratories A major global pharmaceutical company, Abbott has manufacturing capabilities that can encompass API production for its branded and generic drug portfolios.
• Teva Pharmaceutical Industries Ltd. Teva, a leading global generics manufacturer, possesses significant API manufacturing capacity and is a key supplier of carbamazepine. Their operations adhere to stringent international regulatory requirements.
• Sun Pharmaceutical Industries Ltd. As one of India's largest pharmaceutical companies, Sun Pharma has extensive API manufacturing facilities and a strong presence in the global market for various drug substances, including carbamazepine.
• Granules India Ltd. Granules India is a significant producer of pharmaceutical intermediates and APIs. They are recognized for their backward integration and robust manufacturing processes for key therapeutic agents like carbamazepine.
• IOL Chemicals and Pharmaceuticals Ltd. This Indian company manufactures a range of APIs and specialty chemicals. They are a notable supplier of carbamazepine, emphasizing quality and cost-effectiveness.

The production of carbamazepine API requires specialized chemical synthesis processes and adherence to strict quality control measures to ensure purity, potency, and absence of impurities. Regulatory filings, such as Drug Master Files (DMFs), are typically submitted to health authorities like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) by these API manufacturers.

What are the Key Contract Manufacturing Capabilities for Carbamazepine?

Beyond in-house API production, many pharmaceutical companies rely on Contract Development and Manufacturing Organizations (CDMOs) to produce finished dosage forms of carbamazepine. These CDMOs offer specialized expertise in formulation development, clinical trial manufacturing, and commercial-scale production.

Key CDMO capabilities relevant to carbamazepine include:

• Tableting:
  • Immediate-Release Tablets: Standard tablet manufacturing processes involving granulation, compression, and coating.
  • Extended-Release Tablets: Specialized technologies such as matrix tablets, osmotic pump systems, or multi-layer tablets to control drug release over time. This often involves specific excipients and manufacturing equipment. Examples of such technologies include hydrophilic matrix systems and coated beads.
• Oral Suspensions: Manufacturing liquid formulations requiring expertise in particle size control, viscosity modification, and taste masking.
• Capsule Filling: Producing hard-shell or soft-gel capsules containing carbamazepine powder or granules.
• Analytical Services: Comprehensive testing for quality control, including identification, assay, impurity profiling, dissolution testing, and stability studies. These services are critical for ensuring compliance with pharmacopeial standards (e.g., USP, EP).
• Regulatory Support: Assistance with dossier preparation, site inspections, and post-approval changes.

Leading CDMOs with capabilities relevant to carbamazepine finished dosage forms include:

• Catalent Pharma Solutions: Offers broad formulation development and manufacturing services, including solid oral dosage forms.
• Thermo Fisher Scientific (Patheon): A major CDMO providing end-to-end services from drug substance to commercial drug product manufacturing.
• Recipharm: A global pharmaceutical contract manufacturer with expertise in solid dosage forms and oral liquids.
• Ashland Global Holdings Inc.: While primarily an excipient supplier, Ashland also offers formulation development services that can support carbamazepine product design.
• Lonza: Offers comprehensive pharmaceutical development and manufacturing services, including solid dosage forms.

The selection of a CDMO involves evaluating their GMP compliance, regulatory track record, technological capabilities, capacity, and cost-effectiveness.

How is Carbamazepine Regulated?

The manufacturing and distribution of carbamazepine are subject to stringent regulatory oversight by health authorities worldwide. Key regulatory bodies and their requirements include:

• U.S. Food and Drug Administration (FDA):

  • Current Good Manufacturing Practices (cGMP): All facilities manufacturing carbamazepine API and finished drug products must comply with cGMP regulations (21 CFR Parts 210 and 211). This includes requirements for quality systems, personnel, facility design, equipment, production and process controls, laboratory controls, and record-keeping.
  • Drug Master Files (DMFs): API manufacturers submit DMFs to the FDA, providing confidential detailed information about facilities, processes, and controls used in the manufacturing, processing, packaging, and storing of the drug substance.
  • Abbreviated New Drug Applications (ANDAs): Generic drug manufacturers submit ANDAs to demonstrate bioequivalence and pharmaceutical equivalence to the reference listed drug.

• European Medicines Agency (EMA) and National Competent Authorities:

  • European Pharmacopoeia (Ph. Eur.): Carbamazepine must meet the quality standards specified in the European Pharmacopoeia monograph.
  • Good Manufacturing Practice (GMP): Facilities must comply with EU GMP guidelines.
  • Marketing Authorization Applications (MAAs): Similar to ANDAs, MAAs are required for the approval of generic medicinal products.

• Other International Regulatory Agencies: Agencies such as Health Canada, Japan's Pharmaceuticals and Medical Devices Agency (PMDA), and Australia's Therapeutic Goods Administration (TGA) have comparable regulatory frameworks.

Key Regulatory Considerations:

• Impurity Profiling: Manufacturers must identify, quantify, and control process-related impurities and degradation products. Regulatory limits for genotoxic impurities are particularly strict.
• Quality by Design (QbD): Adoption of QbD principles is increasingly encouraged to build quality into the manufacturing process from the outset.
• Supply Chain Security: Regulations are evolving to enhance the security of the pharmaceutical supply chain, including measures against counterfeit drugs.
• Pharmacovigilance: Post-market surveillance and reporting of adverse drug reactions are mandatory.

What are the Current Market Dynamics for Carbamazepine?

The market for carbamazepine is mature, with a significant portion dominated by generic products. Key market dynamics include:

• Price Sensitivity: As a widely available generic, pricing is a significant competitive factor among manufacturers and suppliers.
• Global Demand: Carbamazepine remains a first-line treatment for epilepsy and bipolar disorder in many regions, ensuring sustained demand. The World Health Organization (WHO) Essential Medicines List contributes to this consistent demand [1].
• Competition: Numerous API manufacturers and generic drug producers compete in the market, leading to competitive pricing and a need for efficient production.
• Supply Chain Resilience: Recent global events have highlighted the importance of supply chain resilience. Companies are increasingly focused on diversifying supplier bases and ensuring continuity of supply.
• Geographic Production Centers: A substantial portion of carbamazepine API and finished dosage form manufacturing is concentrated in India and China due to cost advantages and established pharmaceutical manufacturing infrastructure. However, European and North American manufacturers also play a role, particularly for specialized or high-volume markets.

Major Market Players (by general market presence, not exhaustive list):

• Generic Pharmaceutical Companies: Teva Pharmaceuticals, Sun Pharmaceutical Industries, Mylan N.V. (now part of Viatris), Aurobindo Pharma.
• API Manufacturers: Granules India, IOL Chemicals and Pharmaceuticals, Dishman Carbogen Amcis.

The market is characterized by a balance between established players and newer entrants, with continuous efforts to optimize production costs and maintain regulatory compliance.

What are Potential Supply Chain Risks for Carbamazepine?

Several factors can pose risks to the consistent supply of carbamazepine:

• Geopolitical Instability: Disruptions in regions with significant manufacturing capacity (e.g., India, China) due to political unrest, trade disputes, or natural disasters can impact global supply.
• Raw Material Availability and Price Fluctuations: The synthesis of carbamazepine relies on specific chemical precursors. Shortages or price volatility of these raw materials can affect API production costs and availability.
• Regulatory Changes and Compliance Issues: Stricter impurity limits, evolving GMP requirements, or facility non-compliance leading to production shutdowns can disrupt supply. Any significant issue with a major API supplier's regulatory status can have a ripple effect.
• Logistical Challenges: Transportation delays, port congestion, or increased freight costs can affect the timely delivery of APIs and finished products.
• Natural Disasters and Pandemics: Unforeseen events like pandemics or extreme weather can impact manufacturing operations, labor availability, and transportation networks, as demonstrated by the COVID-19 pandemic.
• Quality Control Failures: Batch rejections due to quality control failures at the API or finished product manufacturing stage can lead to significant supply shortages.
• Intellectual Property Issues: While carbamazepine is a well-established generic, any unexpected patent challenges or disputes related to specific manufacturing processes or formulations could, in theory, create short-term supply disruptions for certain products.

Mitigation strategies include maintaining diversified supplier relationships, establishing strategic inventory levels, conducting regular supply chain risk assessments, and ensuring robust quality management systems across all tiers of the supply chain.

Key Takeaways

• Carbamazepine API is manufactured by multiple global suppliers, with significant capacity in India.
• Contract Development and Manufacturing Organizations (CDMOs) are crucial for producing finished dosage forms, particularly extended-release tablets and oral suspensions.
• Stringent regulatory oversight by agencies like the FDA and EMA governs all aspects of carbamazepine production and quality.
• The market is mature and generic-dominated, characterized by price competition and a need for efficient manufacturing.
• Supply chain risks include geopolitical factors, raw material volatility, regulatory compliance, and logistical challenges.

Frequently Asked Questions

1. What are the primary therapeutic indications for carbamazepine?

Carbamazepine is primarily indicated for the treatment of epilepsy (partial seizures and generalized tonic-clonic seizures), trigeminal neuralgia, and bipolar disorder.

2. How does the extended-release formulation of carbamazepine differ in manufacturing from immediate-release?

Extended-release formulations require specialized technologies such as matrix systems, osmotic pumps, or controlled-release coatings to achieve a sustained drug release profile. This contrasts with immediate-release tablets, which are designed for rapid dissolution and absorption.

3. Which regulatory bodies are most critical for carbamazepine API manufacturers to comply with?

API manufacturers must comply with regulations from major health authorities where their products are intended for use, primarily the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA) and its member state authorities, and comparable agencies in other key markets.

4. What is the typical impurity profile that carbamazepine manufacturers must monitor?

Manufacturers must monitor process-related impurities (e.g., starting materials, intermediates) and degradation products. Specific attention is paid to controlled substances and potential genotoxic impurities, adhering to strict limits set by pharmacopoeias and regulatory agencies.

5. How has the global supply chain for carbamazepine been affected by recent geopolitical events or pandemics?

Recent events have highlighted vulnerabilities, leading to increased focus on supply chain diversification, strategic inventory management, and risk mitigation planning by both API manufacturers and finished dosage form producers. This includes identifying alternative sourcing for raw materials and ensuring redundancy in manufacturing sites where feasible.

Citations

[1] World Health Organization. (2023). World Health Organization Model List of Essential Medicines, 23rd List. https://www.who.int/publications/i/item/WHOM MLEM2023